Table 1 Univariate and multivariate Cox analyses of the NRG signature
From: A novel necroptosis signature for predicting survival in lung adenocarcinoma
Variables | Univariate Cox analysis | Multivariate Cox analysis | ||
|---|---|---|---|---|
HR (95% CI) | P | HR (95% CI) | P | |
Training cohort | ||||
NRG signature (high vs. low) | 2.480 (1.798–3.419) | < 0.001 | 2.074 (1.400-3.073) | < 0.001 |
Age (≥ 65 vs. < 65 years) | 1.210 (0.883–1.657) | 0.235 | ||
Gender (male vs. female) | 1.047 (0.768–1.426) | 0.773 | ||
Tumor stage (stage 3–4 vs. 1–2) | 2.805 (2.027–3.882) | < 0.001 | 1.774 (1.039–3.029) | 0.036 |
Smoking (yes vs. no) | 0.894 (0.568–1.406) | 0.627 | ||
T (T 3–4 vs. 1–2) | 2.405 (1.606–3.603) | < 0.001 | 1.438 (0.865–2.390) | 0.161 |
M (positive vs. negative) | 1.857 (1.062–3.247) | 0.03 | 1.031 (0.524–2.029) | 0.929 |
N (positive vs. negative) | 2.642 (1.930–3.618) | < 0.001 | 1.771 (1.137–2.758) | 0.011 |
Validation cohort | ||||
NRG signature (high vs. low) | 2.003 (1.367–2.935) | < 0.001 | 2.026 (1.371–2.993) | < 0.001 |
Age (≥ 65 vs. < 65 years) | 1.379 (0.889–2.137) | 0.151 | ||
Gender (male vs. female) | 1.552 (1.072–2.246) | 0.020 | 1.521 (1.039–2.226) | 0.031 |
Tumor stage (stage 3–4 vs. 1–2) | 2.607 (1.736–3.914) | < 0.001 | 2.881 (1.905–4.358) | < 0.001 |
Smoking (yes vs. no) | 1.369 (0.597–3.139) | 0.459 | ||
KRAS mutation (positive vs. negative) | 1.456 (1.001–2.118) | 0.049 | 1.249 (0.851–1.833) | 0.256 |
EGFR mutation (positive vs. negative) | 0.262 (0.096–0.710) | 0.008 | 0.340 (0.123–0.938) | 0.037 |
TP53 mutation (positive vs. negative) | 1.235 (0.820–1.860) | 0.313 | ||